...found a path to becoming public by acquiring a majority stake of fellow infectious company Cempra Inc.... ...shareholders will own approximately 52% of the combined company; Cempra shareholders will own the remainder. Cempra... ...companies said Cempra is looking for non-dilutive funding to support a safety trial for Solithera. Cempra Inc....
...found a path to becoming public by acquiring a majority stake of fellow infectious company Cempra Inc.... ...shareholders will own approximately 52% of the combined company; Cempra shareholders will own the remainder. Cempra... ...trial for Solithera. Cempra lost $0.15 to $3.65 on Wednesday.
Elizabeth S. Eaton
IV delafloxacin
IV Solithera
Oral delafloxacin
Oral Solithera
Cempra Inc.
Melinta...
...EMA will require additional data for approval. FDA issued complete response letters in December for Cempra’s... ...company plans to resubmit both applications with the additional data requested by FDA. In February, Cempra... ...letter and discussions with FDA (see BioCentury, March 6 ). Solithera is a fluoroketolide/macrolide antibiotic. Cempra...
...seek accelerated approval of Opdivo nivolumab in combination with Yervoy ipilimumab to treat lung cancer Cempra Inc.... ...Inc. (NYSE:MRK) Solithera solithromycin fails in the Phase III SOLITAIRE-U trial to treat gonorrhea, and Cempra...
...evaluable population, Solithera led to a 91.3% success rate vs. 100% for ceftriaxone plus azithromycin. Cempra... ...Research and Development Agreement (CRADA). The expansion is enrolling up to 76 women and adolescents. Cempra... ...rights outside countries in the Association of Southeast Asian Nations (ASEAN) to solithromycin from Merck. Cempra Inc....
...found a path to becoming public by acquiring a majority stake of fellow infectious company Cempra Inc.... ...shareholders will own approximately 52% of the combined company; Cempra shareholders will own the remainder. Cempra... ...companies said Cempra is looking for non-dilutive funding to support a safety trial for Solithera. Cempra Inc....
...found a path to becoming public by acquiring a majority stake of fellow infectious company Cempra Inc.... ...shareholders will own approximately 52% of the combined company; Cempra shareholders will own the remainder. Cempra... ...trial for Solithera. Cempra lost $0.15 to $3.65 on Wednesday.
Elizabeth S. Eaton
IV delafloxacin
IV Solithera
Oral delafloxacin
Oral Solithera
Cempra Inc.
Melinta...
...EMA will require additional data for approval. FDA issued complete response letters in December for Cempra’s... ...company plans to resubmit both applications with the additional data requested by FDA. In February, Cempra... ...letter and discussions with FDA (see BioCentury, March 6 ). Solithera is a fluoroketolide/macrolide antibiotic. Cempra...
...seek accelerated approval of Opdivo nivolumab in combination with Yervoy ipilimumab to treat lung cancer Cempra Inc.... ...Inc. (NYSE:MRK) Solithera solithromycin fails in the Phase III SOLITAIRE-U trial to treat gonorrhea, and Cempra...
...evaluable population, Solithera led to a 91.3% success rate vs. 100% for ceftriaxone plus azithromycin. Cempra... ...Research and Development Agreement (CRADA). The expansion is enrolling up to 76 women and adolescents. Cempra... ...rights outside countries in the Association of Southeast Asian Nations (ASEAN) to solithromycin from Merck. Cempra Inc....